MicroPort, No. 1601 Zhangdong Road, Shanghai (2025)

29/07/2025

® announced the successful first implantation of its ® Left Atrial Appendage Closure System in Hong Kong, China in July. The groundbreaking procedure was performed at Canossa Hospital - Hong Kong Asia Heart Centre, marking a significant milestone in the adoption of next-generation technology in the region.

The AnchorMan® LAAC system was used to significantly reduce the risk of stroke in a patient with atrial fibrillation by sealing off the left atrial appendage, demonstrating exceptional device performance and procedural success. At Canossa Hospital - Hong Kong Asia Heart Centre, the procedure was led by Professor LAM Yat Yin and Dr. Ivan WONG Man Ho, who successfully implanted the device in an elderly patient using a minimally invasive approach. The patient exhibited rapid postoperative recovery with no complications, underscoring the efficacy of the system.

We are honored to collaborate with Canossa Hospital - Hong Kong Asia Heart Centre and distinguished key opinion leaders from China to introduce the AnchorMan® system. These landmark procedures reinforce our commitment to providing cutting-edge cardiovascular solutions that improve patient outcomes and quality of life.

We would like to extend our appreciation to the clinical teams for their exceptional skill and commitment to advancing structural heart disease treatment.

28/07/2025

announced the successful completion of the first five implants of its next-generation Liberty® Transcatheter Aortic Valve Implantation (TAVI) system in Brazil in July, mark a significant advancement in accessible, innovative structural heart therapies for Brazilian patients.
The milestone implants were led by a distinguished team of Brazilian physicians: Dr. José Mariani Jr, Dr. Guy Prado, Dr. Pedro Nicz, Dr. Ricardo Ghetti, Dr. Edgard Quintella, Dr. Eduardo Pessoa de Melo, and Dr. Pedro Lemos

With Dr. Matías Sztejfman serving as the Lead Proctor, the cases demonstrated the system's exceptional clinical performance—including rapid postoperative recovery via minimally invasive approaches and successful management of complex anatomies—validating its precision and adaptability.
The procedures leveraged a strategic partnership between the technical teams of Albert Einstein Israelite Hospital (Einstein) and Santa Casa de Misericórdia de São Paulo in hemodynamic cardiology.

We would like to extend deepest appreciation to the Brazilian physician team for their exceptional skill and dedication and to the Lead Proctor Dr. Matías Sztejfman, for his indispensable expertise and commitment to knowledge transfer.

06/03/2025

is proud to announce that AnchorMan®- Left Atrial Appendage Closure ( ) device, officially received CE MDR certification. This achievement underscores our commitment to advancing medical technology and improving patient care globally.

1️⃣ Unique 12 “3D folding” units at distal, forming a semi-closed structure with a mesh frame, addressing clinical challenges faced by traditional devices that require depth of left atrial appendage.
2️⃣ Round and flexible distal end, reducing potential damage to the tissue, ensuring a more secure and stable anchoring.
3️⃣ The dense nitinol frame is designed to better adapt to the shape of the LAA, improving the sealing effect.
4️⃣ Offering both “ Unsheathe” and “Advanced” release mode, for the physician during the procedure, ensuring optimal placement.

07/02/2025

is proud to celebrate the first two cases of VitaFlow Liberty® in Armenia

Congratulations to Dr. Armen Okroyan and University hospital of Erevan for this significant milestone in cardiac care.

A special thank you to Dr. Timur Imaev for his expert guidance as proctor, playing a vital role in ensuring successful outcomes for these groundbreaking cases.

At , we are dedicated to advancing healthcare innovation, enabling more patients worldwide to live .

30/01/2025

🌟 A huge thank you to all our visitors, partners, and fellow innovators who contributed to making truly extraordinary. Your passion, collaboration, and support have been the driving force behind its success! Let’s carry this momentum forward as we continue striving for better healthcare solutions together.🙌💙

We look forward to welcoming you back next year at 2026 😀✨

28/01/2025

® is proud to announce that its ™ Integrated Coronary Intravascular Lithotripsy System and TomaHawk™ Single-Use Coronary Intravascular Lithotripsy Catheter has officially received NMPA approval on January 26, 2025.

Powered by technology, TomaHawk™ delivers high-impact shockwaves to fracture calcified plaques, improving device deliverability and stent apposition. With real-time pressure monitoring, a proprietary electrode design, and 18 available specifications, TomaHawk™ sets a new standard in calcification pretreatment.

Alongside MicroPort®’s Scoring Balloon and Coronary Rotational Atherectomy System, TomaHawk™ reinforces a comprehensive solution for tackling complex coronary lesions, empowering physicians with advanced tools to enhance patient outcomes.

27/01/2025

On January 26, ®'s Firelimus™ Sirolimus-Coated Coronary Balloon Catheter has officially received NMPA approval! This marks a significant milestone as its the first and only sirolimus-coated balloon catheter approved in the domestic market for the treatment of primary coronary bifurcation lesions.

™ is a flagship product in MicroPort®’s innovative “Intervention Without Implantation” therapeutic portfolio. By utilizing proprietary microcrystalline coating technology, the device ensures rapid drug transfer to vascular tissue and achieves sustained drug release, enhancing treatment efficacy. The drug coating is free from excipients, significantly reducing the risks of vascular inflammation and thrombosis. Moreover, its comprehensive product specifications feature a uniform 40mm balloon length across all diameters, addressing a broader range of clinical needs.

-Coated

26/01/2025

Greetings from Dubai World Trade Centre! 🌍 The MicroPort® team is thrilled to connect with you at ! Join us at booth .C19 as we share our commitment to improving for patients worldwide. Let’s inspire meaningful change together! 💙

20/01/2025

🌟 Join at Arab Health 2025 in Dubai! 🌍

From January 27–30, dive into the future of medical innovation and discover how our cutting-edge technologies are reshaping healthcare:

💡 Advanced Robotics: Experience full-system demos of SkyWalker™, DFVision™, and telesurgery test drives for Toumai™.
💡 Cardiovascular Technologies extending lives and improving outcomes.
💡 Explore our innovations in , , , , and !

📍 Visit us at Booth Z5.C19 to learn how we’re driving through groundbreaking innovation and global partnerships.

23/12/2024

On December 18 2024, FireRaptor™ Integrated Coronary Rotational Atherectomy System (FireRaptor™), an innovative product independently developed and manufactured by , received approval from NMPA for market launch.

FireRaptor™ offers a novel solution for the pretreatment of moderate to severe lesions. Featuring an eccentric diamond-coated burr, it allows operators to adjust rotational speed to modify centrifugal force, thereby controlling the ablation diameter and minimizing the need for device exchanges during procedures. The diamond coating across the entire burr surface further supports radial bidirectional atherectomy, reducing the risk of burr entrapment and enhancing procedural safety.

The approval of FireRaptor™ marks a significant milestone for MicroPort® in advancing treatment solutions for . Together with cutting-edge technologies such as scoring balloons and intravascular lithotripsy systems, FireRaptor™ builds a comprehensive toolkit for tackling resistant coronary lesions, empowering interventional cardiologists with robust pretreatment options so that patients can enjoy .

22/11/2024

is excited to announce the NMPA approval of Firefalcon™ Coronary Scoring Balloon Cathether on November 22! An advanced, domestically developed device designed for ! Featuring a unique scoring mechanism with three scoring elements, Firefalcon™ effectively cracks plaques and enhances vessel dilation. Its longitudinal cutting ability targets atherosclerotic plaques, offering distinct advantages in treating complex lesions, such as in-stent restenosis and calcified plaques.

Firefalcon™ also comes with a comprehensive size range, available in diameters from 2.0 to 4.0mm and additional lengths of 8mm and 18mm, alongside the standard 13mm length. This range offers better adaptability to various clinical needs. With an overall catheter outer diameter reduced by 10-20%, its improved crossability enhances deliverability and facilitates easier navigation through stenotic lesions. Moreover, all sizes feature a higher rated burst pressure of 16atm, ensuring optimal expansion and better treatment outcomes.

This breakthrough marks a significant new milestone in the treatment of complex lesions, setting a new standard for precision and efficacy in interventional cardiology.

19/11/2024

MicroPort CardioFlow Symposium is coming!

We are ready to showcase Liberty’s unique design and review the clinical results of VitaFlow Liberty. There will be a unique networking and collaboration place for global professionals to exchange ideas and forge new relationships that may shape the future of TAVI worldwide.

Join us on Nov 26, 12:15-13:15 at Room 2. We look forward to welcoming you!

MicroPort

29/07/2025

28/07/2025

06/03/2025

07/02/2025

30/01/2025

28/01/2025

27/01/2025

26/01/2025

20/01/2025

23/12/2024

22/11/2024

19/11/2024

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share